Our aim is to assess whether long-term care home (LTCH) ownership and administration type were associated with all-cause mortality in 470 LTCHs in the Community of Madrid (Spain) during March and April 2020, the first two months of the COVID-19 pandemic. There are eight categories of LTCH type, including various combinations of ownership type (for-profit, nonprofit, and public) and administration type (completely private, private with places rented by the public sector, administrative management by procurement, and completely public). Multilevel regression was used to examine the association between mortality and LTCH type, adjusting for LTCH size, the spread of the COVID-19 infection, and the referral hospital. There were 9468 deaths, a mortality rate of 18.3%. Public and private LTCHs had lower mortality than LTCHs under public-private partnership (PPP) agreements. In the fully adjusted model, mortality was 7.4% (95% CI, 3.1-11.7%) in totally public LTCHs compared with 21.9% (95% CI, 17.4-26.4%) in LTCHs which were publicly owned with administrative management by procurement. These results are a testimony to the fatal consequences that pre-pandemic public-private partnerships in long-term residential care led to during the first months of the COVID-19 pandemic in the Community of Madrid, Spain.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620910PMC
http://dx.doi.org/10.3390/epidemiologia3030025DOI Listing

Publication Analysis

Top Keywords

administration type
12
madrid spain
12
long-term care
8
ownership administration
8
all-cause mortality
8
march april
8
april 2020
8
community madrid
8
months covid-19
8
covid-19 pandemic
8

Similar Publications

Current perspectives and the future of disease-modifying therapies in type 1 diabetes.

World J Diabetes

January 2025

Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Preston PR2 9HT, United Kingdom.

Use of immunomodulating agents to prevent the progression of autoimmune β-cell damage leading to type 1 diabetes mellitus (T1DM) is an interesting area for research. These include non-specific anti-inflammatory agents, immunologic vaccination and anti-inflammatory agents targeting specific immune cells or cytokines. Teplizumab is an anti-CD3-molecule that binds to and leads to the disappearance of the CD3/TCR complex and rendering the T cell anergic to its target antigen.

View Article and Find Full Text PDF

Protein nanoparticles as potent delivery vehicles for polycytosine RNA-binding protein one.

World J Diabetes

January 2025

State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Pharmacy, Jinan University, Guangzhou 511436, Guangdong Province, China.

Ma recently reported in the that ferroptosis occurs in osteoblasts under high glucose conditions, reflecting diabetes pathology. This condition could be protected by the upregulation of the gene encoding polycytosine RNA-binding protein 1 (PCBP1). Additionally, Ma used a lentivirus infection system to express PCBP1.

View Article and Find Full Text PDF

The orb-weaver spider genus Archer, 1960 from China is revised, and three species, including two new species, are recognized: Mi & Wang, (♂♀) from Xizang and Mi & Wang, (♂♀) from Hainan; the type species, (Strand, 1906) (♂♀), is redescribed based on specimens from Guizhou and Hubei. A distributional map of the studied specimens is also provided.

View Article and Find Full Text PDF

Background: The objective of this study was to determine the conditioning factors for scientific research productivity in university students of health sciences.Scientific productivity, in addition to making visible the generation of new knowledge, contributes to the well-being of the population and provides feedback to the scientific community in terms of methodologies, perspectives and results that help to break down barriers that delimit productivity in scientific research.

Methods: A cross-sectional analytical observational study was conducted.

View Article and Find Full Text PDF

Pros and Cons of Inpatient SGLT2i Use for Hyperglycemia and Heart Failure.

J Endocr Soc

January 2025

Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Division of Endocrinology, Diabetes and Metabolism, Long Island Jewish Medical Center, Northwell Health, New Hyde Park, NY 11040, USA.

Sodium-glucose cotransporter 2 inhibitors (SGLT2is), originally approved by the US Food and Drug Administration for glycemic control in type 2 diabetes mellitus (DM2), have shown substantial cardiovascular and renal benefits, leading to their expanded use in managing heart failure (HF) and chronic kidney disease in the outpatient setting. Despite these benefits, their use for inpatient hyperglycemia management is not universally endorsed due to safety concerns and inadequate data. However, emerging evidence suggests potential advantages of initiating SGLT2i treatment for patients during hospitalization in the setting of HF.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!